Table 9.
Selected clinical studies in NHL that incorporate lenalidomide.
| Drug Combination | Mode of Action of the Drug Combination | Study Phase | Target Population | Estimated Study Completion Date | GovTrial Denominator |
|---|---|---|---|---|---|
| Brentuximab vedotin + lenalidomide + rituximab | anti-CD30 antibody-drug conjugate brentuximab-vedotin, anti-CD20 rituximab | 3 | R/R DLBCL | December 2025 | NCT04404283 |
| Lenalidomide + R-ICE | anti-CD20 rituximab, chemotherapy ifosfamide, carboplatin, etoposide (ICE) | 1/2 | R/R DLBCL | December 2025 | NCT02628405 |
| lenalidomide + R-CHOP | chemotherapy regimen R-CHOP | 2 | DLBCL (CNS prophylaxis) | October 2024 | NCT04544059 |
| Lenalidomide + R-GemOx | anti-CD20 rituximab, gemcitabine, oxaliplatin | 1 | Newly dg. elderly DLBCL | December 2024 | NCT04432402 |
| Lenalidomide + Rituximab + Dexamethasone | anti-CD20 rituximab | 2 | Newly dg. elderly DLBCL | March 2021 | NCT02955823 |
| Axicabtagene Ciloleucel + rituximab or lenalidomide | anti-CD20 rituximab | 1 | R/R DLBCL | September 2036 | NCT04002401 (Zuma-14) |
| Brentuximab vedotin + lenalidomide + rituximab | anti-CD30 antibody-drug conjugate brentuximab-vedotin, anti-CD20 rituximab | 3 | R/R DLBCL | December 2025 | NCT04404283 |
| lenalidomide + obinutuzumab + venetoclax | anti-CD20 obinutuzumab, BCL2 inhibitor venetoclax | 1/2 | Newly dg. FL | November 2026 | NCT03980171 (LEVERAGE) |
| Lenalidomide + Acalabrutinib + Rituximab | BTK inhibitor acalabrutinib, anti-CD20 rituximab | 2 | Newly dg. FL | March 2025 | NCT04404088 |
| Venetoclax, Lenalidomide and Rituximab | BCL2 inhibitor venetoclax, anti-CD20 antibody rituximab | 1 | Newly dg. MCL | July 2022 | NCT03523975 |
| Lenalidomide + Acalabrutinib + Rituximab | BTK inhibitor acalabrutinib, anti-CD20 rituximab | 2 | Newly dg. MCL | November 2024 | NCT03863184 |
| Venetoclax, Lenalidomide and Rituximab | BCL2 inhibitor venetoclax, anti-CD20 antibody rituximab | 1/2 | R/R MCL | June 2022 | NCT03505944 (VALERIA) |
| Carfilzomib + Lenalidomide + Dexamethasone | Irreversible proteasome inhibitor carfilzomib | 1 | R/R MCL (ibrutinib refractory) | April 2022 | NCT03891355 (FIL_KLIMT) |
| Lenalidomide maintenance | 2 | R/R T-NHL (after salvage therapy) | November 2023 | NCT03730740 (Lemon-T) | |
| Lenalidomide + Brentuximab Vedotin | anti-CD30 antibody-drug conjugate brentuximab-vedotin | 1 | R/R PTCL | August 2021 | NCT03302728 |
| Lenalidomide + Ibrutinib + Rituximab | BTK inhibitor ibrutinib, anti-CD20 rituximab | 1 | primary/secondary CNS lymphoma | November 2021 | NCT03703167 |
Abbreviations: BCL2= B-cell lymphoma; B-NHL= B cell non-Hodgkin lymphomas; BTK= Bruton tyrosine-kinase; MCL= mantle cell lymphoma; GemOx= gemcitabine and oxaliplatin; R/R= relapsed/refractory.